Esophageal manifestation in patients with scleroderma

paythelady.612 shared this article with you from Inoreader Esophageal manifestation in patients with scleroderma Μέσω pubmed: "world j clin cases"... World J Clin Cases. 2021 Jul 16;9(20):5408-5419. doi: 10.12998/wjcc.v9.i20.5408. ABSTRACT The esophagus is the most commonly affected part of the gastrointestinal system in patients with systemic sclerosis (SSc). Esophageal involvement may lead to a significant reduction in patient quality of life. The exact pathophysiology is complex and not yet fully elucidated. Ultimately, esophageal smooth muscle becomes atrophied and replaced by fibrous tissue leading to severe motility disturbance of the distal esophagus. Symptoms are mainly attributed to gastroesophageal reflux disease and to esophageal dysmotility. Compelling evidence has correlated esophageal involvement to the severity of pulmonary disease. No formed guidelines exist about the diagnostic modalities used to assess esophageal disease in patients with SSc, though upper gastrointestinal endoscopy is the first and most important modality used as it can reveal alterations commonly observed in patients with SSc. Further exploration can be made by high resolution manometry and pH-impedance study. Proton pump inhibitors remain the mainstay of treatment, while prokinetic agents are commonly used as add-on therapy in patients with symptoms attributed to gastroesophageal reflux disease not responding to standard therapy as well as to motility disturbances. Gastroesophageal reflux disease symptoms in patients with SSc are frequently difficult to manage, and new therapeutic modalities are emerging. The role of surgical treatment is restricted and should only be preserved for resistant cases. PMID:34307594 | PMC:PMC8281422 | DOI:10.12998/wjcc.v9.i20.5408 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.